HC Wainwright initiated coverage on shares of PDS Biotechnology (NASDAQ:PDSB) in a report issued on Tuesday morning, FlyOnTheWall reports. The brokerage issued a buy rating and a $7.00 price target on the stock.
Separately, Chardan Capital began coverage on shares of PDS Biotechnology in a research note on Wednesday, October 23rd. They set a buy rating and a $10.00 price objective on the stock.
Shares of PDSB opened at $2.92 on Tuesday. The company has a current ratio of 5.35, a quick ratio of 5.35 and a debt-to-equity ratio of 0.04. The company has a market cap of $15.53 million, a P/E ratio of -0.16 and a beta of 2.38. PDS Biotechnology has a 1 year low of $2.80 and a 1 year high of $17.00.
PDS Biotechnology Company Profile
PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.
Further Reading: The four types of profit margin
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.